The company is a pre-revenue clinical-stage biotech with no active pipeline, now a cash-rich shell seeking a strategic transaction. Monitor for announcements of a reverse merger, acquisition target, or new research partnership. The $12M raise provides a runway for deal-making, but the stock is purely a binary event play on management's ability to execute a pivot.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 13 $1.06entry
- T+1 · 3mo ago +0.94%α +1.14% · $1.07
- T+5 · 3mo ago +30.19%α +32.15% · $1.38
- T+20 · 2mo ago +161.32%α +163.07% · $2.77
- T+60 · 11d ago +213.21%α +218.68% · $3.32
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Indaptus Therapeutics reported Q2 2026 results with no active clinical programs, having discontinued its Decoy20 study. Net loss narrowed to $1.8M from $5.2M YoY, driven by cost cuts. The company raised $12M in a June private placement, boosting cash to ~$11.6M, but is now a cash-burning shell evaluating strategic alternatives, including potential acquisitions or investments in new research areas like neurological disorders. The stock is a speculative story on the company's ability to execute a pivot, with no pipeline value.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $1.8M, down from $5.2M in Q2 2025.
- Cash, cash equivalents, and short-term investments totaled $11.6M as of June 30, 2026.
- Completed a $12.0M private placement on June 17, 2026, issuing 20M shares at $0.60/share.
- Discontinued further enrollment in the Decoy20 combination study; no active clinical development programs.
- Began a research collaboration in neurological disorders and sleep as an extension of immunotherapy research.
- All outstanding Series AA and Series AAA Preferred Stock converted into common stock during Q1 2026.
- Annual meeting held August 10, 2026; all director nominees elected and 2026 Equity Incentive Plan approved.
Financial Impact
Net loss improved by $3.4M YoY to $1.8M; cash position strengthened by $12M private placement to $11.6M.
Risk Factors
- No active clinical programs or revenue; company is a cash-burning shell.
- Dilution from the 20M-share June private placement (shares outstanding rose from 2.2M to 133.2M post-split).
- Going concern risk remains if a strategic transaction is not consummated before cash is depleted.
- Nasdaq continued-listing risk cited in forward-looking statements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037574 |
| Document: form8-k.htm | 0001493152-26-037574 |
| Document: 0001493152-26-037574-index-headers.html | 0001493152-26-037574 |
| Document: 0001493152-26-037574-index.html | 0001493152-26-037574 |
| Document: 0001493152-26-037574.txt | 0001493152-26-037574 |
| 8-K Data (Synthetic) | 0001493152-26-037574 |
Track record
20 reports on INDP
4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers